Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Mehreen S. Datoo(University of Oxford), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Nicola Williams(University of Oxford), Sean C. Elias(University of Oxford), Louis Fries(Novavax (United States)), Reshma Kailath(University of Oxford), Eli Rouamba(Institut de Recherche en Sciences de la Santé), Jenny M. Reimer(Novavax (Sweden)), Fernando Ramos Lopez(University of Oxford), Karim Derra(Institut de Recherche en Sciences de la Santé), Duncan Bellamy(University of Oxford), Rachidatou Soma(Institut de Recherche en Sciences de la Santé), Andrés Noé(University of Oxford), Gregory M. Glenn(Agricultural Research Service), Katie Ewer(University of Oxford), Adrian V. S. Hill(University of Oxford), Alison M. Lawrie(University of Oxford), Faizatou Sorgho(Institut de Recherche en Sciences de la Santé), Benedict Orindi(Kenya Medical Research Institute), Hamtandi Magloire Natama(Research Institute of Health Sciences), Umesh Shaligram(Serum Institute of India (India)), Seydou Sawadogo(Institut de Recherche en Sciences de la Santé), Moubarak Tegneri(Institut de Recherche en Sciences de la Santé), Prisca Yameogo(Institut de Recherche en Sciences de la Santé), Florence Ouédraogo(Institut de Recherche en Sciences de la Santé), Amy Flaxman(University of Oxford), Ekta Mukhopadhyay(University of Oxford), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Ousmane Traoré(Institut de Recherche en Sciences de la Santé), Daniel Valia(Institut de Recherche en Sciences de la Santé), Rachel Roberts(University of Oxford), Innocent Valéa(Institut de Recherche en Sciences de la Santé), Matthew Cairns(University of London), Federica Cappuccini(University of Oxford)
Cited by 457
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
|Cell|2021|1.2k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
|Cell|2022|1k
Antibody evasion by the P.1 strain of SARS-CoV-2
|Cell|2021|661